Optics tissue-therapy company NuVision Biotherapies has named Joanna Underhill as its new non-executive director. Joanna will provide an integral voice at board level, working closely
Two Studies Find NuVision’s Omnigen Amniotic Membrane Effective in Improving Dry Eye Disease Symptomology Management of DED symptomology is challenging. One in four of us
NuVision – a Nottingham-based company with a product that speeds up healing of eye conditions – has raised a further £1.1m investment. The funding has
The Queen Victoria Hospital NHS Trust and Maidstone and Tunbridge NHS Trust have completed the first NuVision Fellowship Programme auditing patients with corneal disease, who
Andy Hill and Noel Waters join the expanding NuVision Team. Andy is appointed as Chief Executive Officer and Noel as Chief Operating Officer as the
Additional options for the application of amniotic membrane in-clinic NuVision® Biotherapies, a company based in MediCity, Nottingham, manufactures a human amniotic membrane product using the
OmniLenz is a bespoke bandage contact lens that allows for easy application of Omnigen, Tereo® processed amniotic membrane, to the ocular surface in an ambulatory setting, without the need for surgery or sutures.
NuVision is looking to recruit an exceptional and committed clinical project associate to provide oversite to our ongoing clinical and new product testing programmes.
Volunteers are being sought for the research which is being conducted by Aston University’s Eye Clinic in collaboration with Nottingham’s NuVision Biotherapies, a company formed with backing of the University of Nottingham.
Nottingham experts who designed new eyesight-saving products are to launch more products which could speed up treatment while reducing the impact on hospital waiting lists and patient visits following COVID-19 restrictions.
